Dr Reddy's on Thursday said Himachal Pradesh high court has issued an interim injunction restraining them from manufacturing and selling generic version of German drug maker Boehringer Ingelheim's (BI) diabetes drug Jardiance.
The drugmaker said it is reviewing legal options including filing an appeal against the court order.
Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.
Jardiance is top-selling drug for BI in India.
The drugmaker said it is reviewing legal options including filing an appeal against the court order.
Dr Reddy's has launched copies of Jardiance (empagliflozin), which has valid patent in India until 2025. BI has sought restraining order on manufacture and sale of the drug.
Jardiance is top-selling drug for BI in India.
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
